Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 49-56

  Yosifov, Deyan Y ^a,b   Kaloyanov, Kaloyan A ^a   Guenova, Margarita L ^b   Prisadashka, Kamelia ^a   Balabanova, Maria B ^a   Berger, Martin R ^c   Konstantinov, Spiro M ^a,b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b National Specialised Hospital for Active Treatment of Haematological Diseases   (Bulgaria)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alkylphosphocholines; Apoptosis; Autophagy; Curcumin; Cutaneous T cell lymphoma; Cytotoxicity; Erufosine; Miltefosine

Indexed keywords

3 METHYLADENINE; ALKYLPHOSPHOCHOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROTEIN; CHLOROQUINE; CURCUMIN; DNA; ERUFOSINE; LIGHT CHAIN 3 ISOFORM B; MILTEFOSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL VIABILITY; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DNA FRAGMENTATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84890551588     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.011     Document Type: Article

References (53)

1. Li J.Y., Horwitz S., Moskowitz A., Myskowski P.L., Pulitzer M., Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Management and Research 2012, 4:75-89.
2. Krejsgaard T., Vetter-Kauczok C.S., Woetmann A., Lovato P., Labuda T., Eriksen K.W., et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006, 20:1759-1766.
3. Criscione V.D., Weinstock M.A. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology 2007, 143:854-859.
4. Wong H.K., Mishra A., Hake T., Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). British Journal of Haematology 2011, 155:150-166.
5. Campbell J.J., Clark R.A., Watanabe R., Kupper T.S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010, 116:767-771.
6. Burg G., Kempf W., Cozzio A., Feit J., Willemze R., Jaffe E.S., et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. Journal of Cutaneous Pathology 2005, 32:647-674.
7. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Archives of Dermatology 2003, 139:857-866.
8. Wu J., Wood G.S. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Archives of Dermatology 2011, 147:443-449.
9. Zhang C., Li B., Zhang X., Hazarika P., Aggarwal B.B., Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. Journal of Investigative Dermatology 2010, 130:2110-2119.
10. Jain S., Zain J., O'Connor O. Novel therapeutic agents for cutaneous T-Cell lymphoma. Journal of Hematology and Oncology 2012, 5:24.
11. Konstantinov S.M., Topashka-Ancheva M., Benner A., Berger M.R. Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. International Journal of Cancer 1998, 77:778-786.
12. van Blitterswijk W.J., Verheij M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochimica et Biophysica Acta 2013, 1831:663-674.
13. Bagley R.G., Kurtzberg L., Rouleau C., Yao M., Teicher B.A. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemotherapy and Pharmacology 2011, 68:1537-1546.
14. Georgieva M.C., Konstantinov S.M., Topashka-Ancheva M., Berger M.R. Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Letters 2002, 182:163-174.
15. Konstantinov S.M., Eibl H., Berger M.R. BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. British Journal of Haematology 1999, 107:365-380.
16. Zaharieva M.M., Konstantinov S.M., Pilicheva B., Karaivanova M., Berger M.R. Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects. Annals of the New York Academy of Sciences 2007, 1095:182-192.
17. Yosifov D.Y., Todorov P.T., Zaharieva M.M., Georgiev K.D., Pilicheva B.A., Konstantinov S.M., et al. Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemotherapy and Pharmacology 2011, 67:13-25.
18. Gajate C., Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
19. Richardson P.G., Eng C., Kolesar J., Hideshima T., Anderson K.C. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opinion on Drug Metabolism and Toxicology 2012, 8:623-633.
20. Rubel A., Handrick R., Lindner L.H., Steiger M., Eibl H., Budach W., et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiation Oncology 2006, 1:6.
21. Nieto-Miguel T., Gajate C., Mollinedo F. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. Journal of Biological Chemistry 2006, 281:14833-14840.
22. Chiarini F., Del Sole M., Mongiorgi S., Gaboardi G.C., Cappellini A., Mantovani I., et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22:1106-1116.
23. Gills J.J., Dennis P.A. Perifosine: update on a novel Akt inhibitor. Current Oncology Reports 2009, 11:102-110.
24. Hideshima T., Catley L., Yasui H., Ishitsuka K., Raje N., Mitsiades C., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
25. Dineva I.K., Zaharieva M.M., Konstantinov S.M., Eibl H., Berger M.R. Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. Journal of Cancer Research and Clinical Oncology 2012, 138:1909-1917.
26. Yosifov D.Y., Reufsteck C., Konstantinov S.M., Berger M.R. Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leukemia Research 2012, 36:764-772.
27. Kapoor V., Zaharieva M.M., Das S.N., Berger M.R. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Letters 2012, 319:39-48.
28. Dummer R., Krasovec M., Roger J., Sindermann H., Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. Journal of the American Academy of Dermatology 1993, 29:963-970.
29. Dummer R., Roger J., Vogt T., Becker J., Hefner H., Sindermann H., et al. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. Progress in experimental tumor research Fortschritte der experimentellen Tumorforschung 1992, 34:160-169.
30. Dumontet C., Thomas L., Berard F., Gimonet J.F., Coiffier B. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. Bulletin du Cancer 2006, 93:E115-E118.
31. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends in Pharmacological Sciences 2009, 30:85-94.
32. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters 2008, 269:199-225.
33. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry and Cell Biology 2009, 41:40-59.
34. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as Curecumin: from kitchen to clinic. Biochemical Pharmacology 2008, 75:787-809.
35. Gupta S.C., Patchva S., Koh W., Aggarwal B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clinical and Experimental Pharmacology and Physiology 2012, 39:283-299.
36. Lundberg B.B. Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukaemic cells in culture. Anti-Cancer Drug Design 1997, 12:503-513.
37. Wu Y.T., Tan H.L., Shui G., Bauvy C., Huang Q., Wenk M.R., et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. Journal of Biological Chemistry 2010, 285:10850-10861.
38. Ashfaq U.A., Javed T., Rehman S., Nawaz Z., Riazuddin S. Lysosomotropic agents as HCV entry inhibitors. Virology Journal 2011, 8:163.
39. Leonard R., Hardy J., van Tienhoven G., Houston S., Simmonds P., David M., et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. Journal of Clinical Oncology 2001, 19:4150-4159.
40. Jendrossek V., Hammersen K., Erdlenbruch B., Kugler W., Krugener R., Eibl H., et al. Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemotherapy and Pharmacology 2002, 50:71-79.
41. Fiegl M., Lindner L.H., Juergens M., Eibl H., Hiddemann W., Braess J., et al. a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemotherapy and Pharmacology 2008, 62:321-329.
42. Rishi L., Dhiman R., Raje M., Majumdar S. Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-kappaB. Biochimica et Biophysica Acta 2007, 1770:1230-1239.
43. Rishi L., Gahlot S., Kathania M., Majumdar S. Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression. Biochemical Pharmacology 2009, 77:30-45.
44. Kepp O., Galluzzi L., Lipinski M., Yuan J., Kroemer G. Cell death assays for drug discovery. Nature Reviews 2011, 10:221-237.
45. Shen S., Kepp O., Kroemer G. The end of autophagic cell death. Autophagy 2012, 8:1-3.
46. Fu L., Kim Y.A., Wang X., Wu X., Yue P., Lonial S., et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Research 2009, 69:8967-8976.
47. Tong Y., Liu Y.Y., You L.S., Qian W.B. Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacologica Sinica 2012, 33:542-550.
48. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research 2005, 65:2422-2432.
49. Krejsgaard T., Kopp K., Ralfkiaer E., Willumsgaard A.E., Eriksen K.W., Labuda T., et al. A novel xenograft model of cutaneous T-cell lymphoma. Experimental Dermatology 2010, 19:1096-1102.
50. Thaler S., Burger A.M., Schulz T., Brill B., Bittner A., Oberholzer P.A., et al. Establishment of a mouse xenograft model for mycosis fungoides. Experimental Dermatology 2004, 13:406-412.
51. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., Aggarwal B.B., et al. (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Molecular Pharmacology 2006, 69:195-206.
52. Liu C.H., Chang F.Y. Development and characterization of eucalyptol microemulsions for topic delivery of curcumin. Chemical and Pharmaceutical Bulletin 2011, 59:172-178.
53. Liu C.H., Chang F.Y., Hung D.K. Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants. Colloids and Surfaces B, Biointerfaces 2011, 82:63-70.